The regenerative medicine company plans to further develop the treatment through partnerships with companies commercialising cancer immunotherapies.
Showing 25 of 3101
The latest investment takes Star Bright’s total interest in the company to 19.99% of issued shares.
US-based Dennis Eck recently purchased a $1 million parcel of shares and now holds more than 5.331 million.
BetterCells is an online platform that aims to connect functional and integrative medical practitioners with people looking to improve their health.
Non-executive director Dennis Eck purchased $1 million worth of stock for 38 cents.
An MOU between the two companies targeting advanced diagnostics and analytical services for clinical trials remains in place.
The investor event starts at 3pm on the main drag of the trendy Perth suburb of Mt Lawley.
The biotechnology company is focused on its R&D program and is funded with a $1.9 million R&D loan from Paddington Street Finance Pty Ltd.
The Hong Kong-based investment company now holds a significant interest of 19.99%.
The offer was at the same price as the recent share placement to sophisticated and institutional investors for $9 million.
Three studies are the focus as the company targets chronic illnesses, including cancer, using a pipeline that includes cannabis products and probiotics.
The research note puts the value per share at 14 cents each, or 12 cents after dilutions.
Opthea Ltd will present at next week's ASX Small and Mid-Cap Conference in Sydney, highlighting its excellent 2017-18 annual report.
The company now has its services being used in a total of eight clinical trials.
Professor David Casarett and Dr Dustin Sulak add clinical expertise and depth to the board.
Arix led a $24 million share placement and will invest $14.2 million in two tranches.
Podiatry is a branch of medicine devoted to the treatment of the foot and ankle.
The company plans to raise funds by way of a share placement.
The halt will remain in place until the start of trade on August 6 or earlier if an announcement is released.
The halt will remain in place until the start of normal trading on Tuesday, 31 July, or when the announcement is released.
The company's lead clinical compound blocks an important tumour survival pathway known as Akt.
The company experienced growth in the European, North American and Asia Pacific-markets, including Australia and New Zealand.
Provisioning the Miya platform across six hospital sites in the Northern Territory.
The two directors purchased a combined $74,000+ worth of shares this week.
Progenza is the company’s lead cell therapy technology platform.